EP
NAMS icon

Essential Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Essential Partners’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8K Buy
53
+51
+2,550% +$1.68K ﹤0.01% 2013
2026
Q1 		$64 Hold
2
– – ﹤0.01% 2771
2025
Q4 		$70 Hold
2
– – ﹤0.01% 2607
2025
Q3 		$57 Hold
2
– – ﹤0.01% 2555
2025
Q2 		$36 Buy
+2
New +$36 ﹤0.01% 2182

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Essential Partners's NAMS Position: Q2 2026 in Review

Essential Partners increased its NewAmsterdam Pharma (NAMS) stake by 2,550% in Q2 2026, buying an estimated $1.68K and bringing the position to 53 shares worth $1.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2013.

Essential Partners first reported a position in NAMS in Q2 2025 and has held it in 5 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Essential Partners held 53 shares of NewAmsterdam Pharma worth $1.8K as of Q2 2026.
  • Essential Partners bought 51 NewAmsterdam Pharma shares in Q2 2026, an estimated $1.68K.
  • NewAmsterdam Pharma made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2013 holding.
  • Essential Partners first reported a position in NewAmsterdam Pharma in Q2 2025 and has held it in 5 quarters since.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.